Hyppää sisältöön
    • Suomeksi
    • In English
Trepo
  • Suomeksi
  • In English
  • Kirjaudu
Näytä viite 
  •   Etusivu
  • Trepo
  • TUNICRIS-julkaisut
  • Näytä viite
  •   Etusivu
  • Trepo
  • TUNICRIS-julkaisut
  • Näytä viite
JavaScript is disabled for your browser. Some features of this site may not work without it.

Prognostic value of psoas muscle area and pleural effusion in patients undergoing TAVI

Järvinen, Otto; Rankinen, Jani; Hernesniemi, Jussi; Virtanen, Marko; Maaranen, Pasi; Eskola, Markku; Oksala, Niku; Tynkkynen, Juho (2026-02)

 
Avaa tiedosto
Prognostic_value_of_psoas_muscle_area_and_pleural_effusion_in_patients_undergoing_TAVI.pdf (378.4Kt)
Lataukset: 



Järvinen, Otto
Rankinen, Jani
Hernesniemi, Jussi
Virtanen, Marko
Maaranen, Pasi
Eskola, Markku
Oksala, Niku
Tynkkynen, Juho
02 / 2026

IJC Heart and Vasculature
101871
doi:10.1016/j.ijcha.2026.101871
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:tuni-202603133215

Kuvaus

Peer reviewed
Tiivistelmä
Background: Radiographic markers such as psoas muscle area (PMA) and pleural effusion have been linked to mortality after transcatheter aortic valve implantation (TAVI). We examined their relationship with cause-specific mortality and their incremental prognostic value beyond EuroSCORE II. Methods: This retrospective study included 1090 consecutive TAVI patients treated at Heart Hospital, Tampere University Hospital between 2008 and 2020. Preoperative CT scans were reviewed for L3-level PMA and pleural effusion (>10 mm thickness). Subdistribution hazard models adjusted for age, sex, BMI, and BSA were used to analyze cause-specific mortality. Incremental prognostic value beyond EuroSCORE II was assessed using time-dependent discrimination indexes (AUC and IDI) and net-reclassification index (NRI) at 3 years. Results: During a median follow-up of 4.3 years (IQR 3.1–6.0), 54% (n = 590) of patients died: 64% (n = 376) from cardiovascular, 30% (n = 177) from non-cardiovascular, and 6% (n = 37) from unnatural causes. PMA and pleural effusion were associated with cardiovascular mortality (PMA: SDH/1SD 0.88, 95% CI 0.78–0.99, p = 0.037; pleural effusion: SDH 1.73, 95% CI 1.37–2.19, p < 0.001). Combined inclusion of PMA and pleural effusion improved NRI = 0.13 (p = 0.004) and IDI = 0.015 (p = 0.004) of overall mortality prediction compared to EuroSCORE II alone. Conclusions: Psoas muscle area (PMA) and pleural effusion were independently associated with cardiovascular mortality after TAVI, whereas no significant associations were observed with non-cardiovascular deaths. Combined inclusion of these parameters led to a modest but not clinically meaningful improvement in the EuroSCORE II–based prediction of mortality.
Kokoelmat
  • TUNICRIS-julkaisut [25372]
Kalevantie 5
PL 617
33014 Tampereen yliopisto
oa[@]tuni.fi | Tietosuoja | Saavutettavuusseloste
 

 

Selaa kokoelmaa

TekijätNimekkeetTiedekunta (2019 -)Tiedekunta (- 2018)Tutkinto-ohjelmat ja opintosuunnatAvainsanatJulkaisuajatKokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy
Kalevantie 5
PL 617
33014 Tampereen yliopisto
oa[@]tuni.fi | Tietosuoja | Saavutettavuusseloste